Page 117 - ESHRE2019

Worldwide HCMV seroprevalence rates among women of reproductive age and birth prevalence of congenital CMV infection10
Why high congenital HCMV birth prevalence inspite of having preexisting antibodies in the mother?
HCMV seroprevalence
Congenital HCMV Birth prevalence
Cytomegalovirus is a much greater global problem than Zika. -Declan Butler, 2016; Nature
Changing Viral Epidemiology: the present‐ equilibrium and interventions
• HCV12 (0.5‐2.3%)? The standard of care for hepatitis C is changing rapidly. Direct Acting Anti‐retrovirals (Sofosbuvir, daclatasvir and the sofosbuvir/ledipasvir combination) are part of the preferred regimens in the WHO guidelines, and can achieve cure rates above 95%. Resistance?
• HIV15,16 (UNAIDS 90:90:90): By the end of 2017, the world had achieved 75–79–81. Globally, 75% of people living with HIV know their status, 79% of people living with HIV who know their status are accessing antiretroviral therapy and 81% of people accessing treatment had suppressed viral loads. Despite the global successes, evidence presented at the workshop showed that entire regions and populations are still being left behind. Progress in eastern Europe and central Asia, western and central Africa and the Middle East and North Africa is falling behind. Key populations, adolescents and men are not being reached by traditional health facility‐based HIV testing services. Lack of political commitment, user fees and stigma and discrimination are some of the barriers to progress. Large disparities exist between countries. While some are close to meeting the UNAIDS 2020goals already, others will require a great deal of progress over the coming years.
112
PRECONGRESS COURSE 12 I VIENNA, AUSTRIA – 23 JUNE 2019 115